

Early attrition in HIV care in South Africa: implications for test and treat

Cheyip M, Ayalew K, Larsen A, Fomundam H, Tesfay A, Aynalem G

CDC South Africa



Department of Health and Human Services
Centers for Disease Control and Prevention



Background

- Linkage to care is essential for the overall HIV response
- Attrition (loss from care) undermines efforts to improve linkage and retention in HIV care
- Improved linkage and retention to HIV care leads to:
 - Better survival
 - Reduced morbidity
 - Decreased transmission
- High quality routine data provide an opportunity to monitor critical outcomes
- This is a secondary analysis of data from Pre-ART surveillance led by Howard University
- The analysis assessed the extent and predictors of early attrition among newly diagnosed HIV positive patients in SA


Methods – Population and setting

- All PLHIV 15 years of age and above diagnosed from Jan – Mar 2015 and followed until Dec 2015
- 34 purposively selected PHC facilities
- Three high burden districts (City of Johannesburg, uThukela, Gert Sibande)
- Record review of programmatic data

Statistical Methods - I

Outcome variable

- **Early attrition** – Never returned for CD4 results after HIV diagnosis
 - ❖ **Phase 1** - Between diagnosis and blood draw for CD4 count
 - ❖ **Phase 2** - Between blood draw and returning for CD4 results



Statistical Methods - II

Potential predictors

- Age, gender, facility location, WHO staging, TB co-infection, district

Logistic regression

- To determine predictors of early attrition

Results – study population

- A total of N=3,744 HIV infected patients were enrolled
- Aged between 15 and 84 years
- Majority were females (68%) and from Gert Sibande district (42%)

Characteristics of study population by gender

| Characteristic at diagnosis | Male | | Female | | P-value |
|--|--------------|-------|--------------|-------|---------|
| N(%) | 1194 (31.89) | | 2550 (68.11) | | |
| Median age (IQR) | 34 (28 – 41) | | 28 (23 – 35) | | |
| | n | % | n | % | |
| Age category | | | | | |
| <20 | 23 | 1.93 | 188 | 7.37 | <0.001 |
| 20-29 | 339 | 28.39 | 1233 | 48.35 | |
| 30-39 | 476 | 39.87 | 724 | 28.39 | |
| 40_49 | 257 | 21.52 | 279 | 10.94 | |
| >=50 | 99 | 8.29 | 126 | 4.96 | |
| TB co-infection | 53 | 4.44 | 29 | 1.14 | <0.001 |
| CD4 value | | | | | |
| <200 | 358 | 43.50 | 435 | 24.53 | <0.001 |
| 200-349 | 211 | 25.64 | 478 | 26.96 | |
| 350-499 | 144 | 17.50 | 434 | 24.48 | |
| >500 | 110 | 13.37 | 426 | 24.03 | |
| WHO staging | | | | | |
| I | 324 | 51.59 | 1043 | 73.76 | <0.001 |
| II | 177 | 28.18 | 266 | 18.81 | |
| III | 116 | 18.47 | 97 | 6.86 | |
| IV | 11 | 1.75 | 8 | 0.57 | |
| ART eligibility at diagnosis (CD4≤500, Tb, pregnancy) | | | | | <0.001 |
| Yes | 738 | 61.81 | 1639 | 64.27 | |
| District | | | | | |
| Gert Sibande | 523 | 43.80 | 1042 | 40.86 | 0.229 |
| City of Johannesburg | 341 | 28.56 | 775 | 30.39 | |
| Uthukela | 330 | 27.64 | 733 | 28.75 | |

- Men were :
 - Older – median age (34 vs 28)
 - Presented late (43 % vs 24%)
- Women were:
 - Clinically healthier (73% vs 51 %)

Results – Early attrition

- There was 28% early attrition recorded
 - 21% (n=788) lost between diagnosis and blood draw
 - 7% (n=277) lost between blood draw and receipt of CD4 results
- Early attrition was more likely in males

Early attrition by demographic characteristics

| Characteristic | Diagnosed N | PHASE 1 n (%) | Providing blood samples for CD4 tests | PHASE 2 n (%) | Early Attrition (Phase 1 + Phase 2) N(%) |
|-----------------------------|-------------|---------------|---------------------------------------|---------------|--|
| All | 3744 | 788 (21.05) | 2956 | 277 (7.40) | 1065 (28.45) |
| Gender | | | | | |
| Female | 2550 | 518 (20.31) | 2032 | 173(6.78) | 691 (27.10) |
| Male | 1,194 | 270(22.61) | 924 | 104 (8.71) | 374 (31.32) |
| Age | | | | | |
| <20 | 211 | 48 (22.75) | 163 | 14 (6.64) | 62(29.38) |
| 20-29 | 1572 | 356 (22.65) | 1216 | 118(7.51) | 474 (30.15) |
| 30-39 | 1200 | 230 (19.17) | 970 | 95(7.92) | 325 (27.08) |
| 40_49 | 536 | 108 (20.15) | 428 | 36(6.72) | 144 (26.87) |
| >=50 | 225 | 46 (20.44) | 179 | 14 (6.22) | 60 (26.67) |
| District | | | | | |
| Gert Sibande | 1565 | 430 (27.48) | 1135 | 151 (9.65) | 581 (37.12) |
| City of Johannesburg | 1116 | 171 (15.32) | 945 | 105 (9.41) | 276 (24.73) |
| Uthukela | 1063 | 187(17.59) | 876 | 21 (1.98) | 208 (19.57) |
| Facility location | | | | | |
| Rural | 519 | 116 (22.35) | 403 | 20 (3.85) | 136 (26.20) |
| Urban Inner City | 176 | 74 (42.05) | 102 | 22 (12.50) | 96 (54.55) |
| Urban Suburb | 549 | 81 (14.75) | 468 | 66 (12.02) | 147 (26.78) |
| Urban Township | 2500 | 517 (20.68) | 1983 | 169 (6.76) | 686 (27.44) |

- Majority lost between diagnosis and blood draw
- Attrition higher in males than females (31% Vs 27%)
- Gert Sibande recorded highest proportion of early attrition (37%)
- In Urban inner cities half of the patients were lost

Predictors of early attrition in care

| Factor | N | Early attrition n | Bivariate OR (95% CI) | Multivariate AOR (95% CI) |
|----------------------------|------|----------------------|-----------------------|---------------------------|
| Gender | | | | |
| Female (ref) | 2550 | 691 | - | - |
| Male | 1194 | 374 | 1.23 (1.06 – 1.43) | 1.26 (1.02 – 1.54) |
| Age category | | | | |
| <20 (ref) | 211 | 62 | - | - |
| 20-29 | 1572 | 474 | 1.04 (0.76 – 1.42) | 1.43 (0.95 – 2.17) |
| 30-39 | 1200 | 325 | 0.89 (0.65 – 1.23) | 1.15 (0.75 – 1.78) |
| 40_49 | 536 | 144 | 0.88 (0.62 – 1.26) | 0.98 (0.62 – 1.56) |
| >=50 | 225 | 60 | 0.87 (0.58 – 1.33) | 1.04 (0.60 – 1.79) |
| Facility location | | | | |
| Urban Township (ref) | 2500 | 686 | - | - |
| Rural | 519 | 136 | 0.94 (0.76 – 1.16) | 1.79 (1.19 – 2.69) |
| Urban Inner City | 176 | 96 | 3.17 (2.33 – 4.32) | 3.77 (2.48 – 5.72) |
| Urban Suburb | 549 | 147 | 0.97 (0.79 – 1.19) | 1.04 (0.76 – 1.41) |
| District | | | | |
| City of Johannesburg (ref) | 1116 | 276 | - | - |
| Gert Sibande | 1565 | 581 | 1.80 (1.52 – 2.13) | 3.63 (2.82 – 4.67) |
| Uthukela | 1063 | 208 | 0.74 (0.60 – 0.91) | 0.89 (0.61 – 1.30) |
| WHO staging | | | | |
| Stage I (ref) | 1367 | 35 | - | - |
| Stage II | 443 | 22 | 1.99 (1.15 – 3.43) | 2.02 (1.16 – 3.48) |
| Stage III | 213 | 3 | 0.54 (0.17 – 1.78) | 0.45 (0.14 – 1.48) |

- Model was adjusted for age and other factors
- Attrition was positively associated with:
 - Male gender
 - Urban inner city and rural vs urban township
 - Gert Sibande vs City of Johannesburg

Limitations

- Representativeness of the sample
- Quality of routine data

Conclusion

- Early attrition was high in SA in 2015
- Encourage strategies that reduce early attrition particularly among men attending facilities in rural and urban inner cities
- Efforts that encourage treatment soon after diagnosis would be beneficial for the SA program

Implications for practice and research

- Universal Test and treat may be beneficial in dealing with attrition (In Sept 2016)
- Continue strengthening strategies to improve entry into care
 - Targeting places where men congregate e.g taxi ranks, VMMC centers
 - Use of community collaborators e.g navigators and champions
 - Phone calls
- Inner cities may be prone to mobility which is a threat to efforts to improve linkage
- More research is needed to identify additional factors associated with attrition

Acknowledgements

- District program Managers (City of Johannesburg, Gert Sibande and Uthukela)
- Public health facilities and patients
- Howard University
- CDC SA ESI team – (Patrick Nadol, Linnetie Mugore, Alfred Musikewa)

This study was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention, under the terms of Cooperative Agreement Number 1U2GGH000391

Disclaimer

"The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention."



Thank you

CDC South Africa

c/o U.S. Embassy

P.O. Box 9536

Pretoria 0001

877 Pretorius St.

Pretoria, South Africa

Phone: +27-12-424-9000 Email: info@sa.cdc.gov

To learn more about CDC, visit www.cdc.gov

To learn more about PEPFAR, visit www.PEPFAR.gov

